315 related articles for article (PubMed ID: 34505024)
21. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
Qi Y; Yan X; Wang C; Cao H; Liu G
Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
[No Abstract] [Full Text] [Related]
23. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Yang F; Wang Y; Tang L; Mansfield AS; Adjei AA; Leventakos K; Duma N; Wei J; Wang L; Liu B; Molina JR
Front Oncol; 2022; 12():955440. PubMed ID: 36052255
[TBL] [Abstract][Full Text] [Related]
24. Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.
Xu H; Ming P; Zhao Z; Zhao N; Zhou D; Tang X; Cao D
Integr Cancer Ther; 2023; 22():15347354231164584. PubMed ID: 36998207
[TBL] [Abstract][Full Text] [Related]
25. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis.
Wu Z; Zhou P; Zhao Y; Wang J; Gao S
Transl Cancer Res; 2024 May; 13(5):2451-2463. PubMed ID: 38881944
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Chen C; Tian P; Zhong J; Fan X
Front Oncol; 2023; 13():1151769. PubMed ID: 37152041
[TBL] [Abstract][Full Text] [Related]
28. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
[TBL] [Abstract][Full Text] [Related]
29. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis.
Mo J; Hu X; Gu L; Chen B; Khadaroo PA; Shen Z; Dong L; Lv Y; Chitumba MN; Liu J
World J Surg Oncol; 2020 Jan; 18(1):15. PubMed ID: 31959178
[TBL] [Abstract][Full Text] [Related]
30. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
31. Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Lin K; Lin J; Huang Z; Fu J; Yi Q; Cai J; Khan M; Yuan Y; Bu J
Front Pharmacol; 2022; 13():881493. PubMed ID: 35645829
[No Abstract] [Full Text] [Related]
32. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
33. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
Peng S; Ying AF; Tai BC; Soo RA
Transl Lung Cancer Res; 2020 Aug; 9(4):1124-1137. PubMed ID: 32953491
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Wang S; Hao J; Wang H; Fang Y; Tan L
Oncoimmunology; 2018; 7(8):e1457600. PubMed ID: 30221052
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
Front Oncol; 2020; 10():574752. PubMed ID: 33585195
[TBL] [Abstract][Full Text] [Related]
36. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.
Kim BJ; Kim JH; Kim HS
Oncotarget; 2017 Aug; 8(31):51779-51785. PubMed ID: 28881686
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Wang Z; Zhou F; Xu S; Wang K; Ding H
Cancer Med; 2023 Sep; 12(18):18516-18530. PubMed ID: 37584242
[TBL] [Abstract][Full Text] [Related]
38. Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis.
Xu H; Cao D; Zhou D; He A; Ge W; Xu X
J Oncol; 2023; 2023():4477263. PubMed ID: 36688004
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
40. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.
Yu S; Zhang S; Xu H; Yang G; Xu F; Yang L; Chen D; An G; Wang Y
BMJ Open; 2023 Mar; 13(3):e059457. PubMed ID: 36931679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
